Delivery Order SPE2DB24D3015-SPE2DB25FGARN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $27,708.84 to AmerisourceBergen Drug Corp for the supply of TYPHIM VI 25 MCG/0.5 ML Vial 10ML, a typhoid vaccine product. This firm fixed price delivery order, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-competitive, non-set-aside procurement executed under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $3,162.72 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 20, 2025, with a completion date of August 21, 2025. This firm fixed-price delivery order is non-competitive and utilizes no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical supply contract. The award represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $6,235.78 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML vial (10 ML) on September 4, 2025, with completion scheduled for September 5, 2025. This delivery order represents a firm fixed price, non-set-aside competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999.00 through December 2026. TYPHIM VI is a typhoid...
- The Defense Logistics Agency awarded a delivery order valued at $18,736.79 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML Vial 10ML, a typhoid vaccine product. This firm fixed price, non-competitive delivery order was issued on June 23, 2025, with an ultimate completion date of June 24, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,086.06 to AmerisourceBergen Drug Corp for the supply of TYPHIM VI 25 MCG/0.5 ML vials (10 mL quantity) on August 25, 2025, with completion scheduled for August 26, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. Performance will be executed from the awardee's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a $37,836.27 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a $1,210.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of TYPHIM VI 25 mcg/0.5 mL vial (10 mL). This is a non-set-aside competitively awarded contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $1,836.60 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML Vial 10ML, a typhoid vaccine product. This non-set-aside, competitively awarded contract represents a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The vaccine will be delivered to AmerisourceBergen's...
- This delivery order, awarded July 23, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $18,963.22 with completion scheduled for July 24, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location, the company's corporate headquarters. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $12,086.06 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML Vial 10ML, a typhoid vaccine product. This firm fixed price, non-set-aside delivery order was awarded on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGARNDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,213.67 for TYPHIM VI 25 MCG/0.5 ML vial (10 mL) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through open competition. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the company's primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and established federal vendor that supplies critical medical commodities to defense and military healthcare systems. The company's contract portfolio with DLA demonstrates its capability to deliver a comprehensive range of pharmaceutical products including vaccines, specialty medications, and medical supplies across multiple therapeutic domains. This specific award for TYPHIM VI typhoid vaccine reflects the company's continued role as a key supplier of immunological products and vaccines to support the medical readiness requirements of the Department of Defense and the military healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/21/25 |